RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Federal Judge Blocks Pentagon's Restrictive Press Access Policy 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Microsoft Backs Anthropic in Legal Fight Against Pentagon's AI Blacklist 
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge 
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement resolves multiple lawsuits accusing Moderna of using the companies’ LNP delivery system without authorization in its mRNA-based vaccine.
Under the terms of the settlement, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion may be paid depending on the outcome of a separate legal appeal. The deal brings closure to both U.S. and international legal actions related to the disputed vaccine technology.
Lipid nanoparticles play a critical role in mRNA vaccines, including Moderna’s COVID-19 shot. The technology acts as a protective carrier that shields fragile messenger RNA molecules and helps deliver them safely into human cells, enabling the vaccine to trigger an immune response. Genevant and Arbutus claimed ownership of key patents covering this LNP delivery system and argued that Moderna used the technology without proper licensing.
As part of the settlement, Moderna stated it will not owe royalties to Genevant or Arbutus for LNP technology in its future vaccine products. This clause removes potential financial uncertainty for the biotech company as it continues developing new vaccines, including updated COVID-19 shots and combination COVID/flu vaccines.
Investors reacted positively to the announcement. Moderna shares surged more than 10% in after-hours trading following the news. Arbutus Biopharma stock climbed approximately 11%, while Roivant Sciences, Genevant’s parent company, saw a modest gain of about 1%.
Analysts believe the settlement removes a significant legal risk for Moderna. According to Jefferies analyst Andrew Tsai, the agreement eliminates the worst-case scenario of paying double-digit royalty rates on vaccine sales. Considering Moderna has generated roughly $48 billion in global COVID-19 vaccine revenue, the settlement amount represents only a small fraction of those earnings.
The case had been scheduled to go to trial in Delaware federal court, marking what would have been the first major trial among several high-stakes patent disputes tied to COVID-19 vaccine technology. Similar lawsuits involving Pfizer and BioNTech remain ongoing, highlighting the intense competition and intellectual property battles within the rapidly evolving mRNA vaccine industry.
